BriefTea
Every story in sixty words
Business · 3 August 2026
Britain's biggest drugmaker is discussing a massive combination with its American counterpart to build a global pharmaceutical titan. Pascal Soriot leads the British firm, which is valued at nearly £196bn before the news emerged. Investors reacted negatively on Monday, sending shares down by more than 7% in early trading.
Reported by Guardian · How we write briefs
More briefs
BusinessIceland supermarket boss tells the Chancellor to cut business taxes for employers BusinessNorwich trains face disruption in September and October for rail works BusinessEngland's free bus pass age will rise to 67 by April 2028 BusinessBritish tourist visits to Japan up 40.8% since 2019 TechnologyGoogle paying £260m to settle UK Play Store developer lawsuit BusinessSnack makers warn new UK rules could undo years of reformulation work More business stories → Browse all stories →